The antibacterial effect of nitric oxide against ESBL-producing uropathogenic E. coli is improved by combination with miconazole and polymyxin B nonapeptide

BMC Microbiology

Katarina Persson²  Bo Söderquist³  Anna Önnberg³  Marie Karlsson¹  Annica Kinnunen¹  Charlotte Sahlberg Bang¹ 

[1] Faculty of Medicine and Health, iRiSC - Inflammatory Response and Infection Susceptibility Centre, Örebro University, SE- 701 82 Örebro, Sweden;School of Medicine, Campus USÖ, Örebro University, SE-701 82 Örebro, Sweden;Department of Laboratory Medicine, Clinical Microbiology, Örebro University Hospital, SE-701 85 Örebro, Sweden

关键词: Polymyxin B nonapeptide;    Nitric oxide;    Extended-spectrum β-lactamase;    Uropathogenic E. coli;   

Others  :  1141651
DOI  :  10.1186/1471-2180-14-65

 received in 2013-11-22, accepted in 2014-03-07,  发布年份 2014

【 摘 要 】

Background

Nitric oxide (NO) is produced as part of the host immune response to bacterial infections, including urinary tract infections. The enzyme flavohemoglobin, coded by the hmp gene, is involved in protecting bacterial cells from the toxic effects of NO and represents a potentially interesting target for development of novel treatment concepts against resistant uropathogenic bacteria. The aim of the present study was to investigate if the in vitro antibacterial effects of NO can be enhanced by pharmacological modulation of the enzyme flavohemoglobin.

Results

Four clinical isolates of multidrug-resistant extended-spectrum β-lactamase (ESBL)-producing uropathogenic E. coli were included in the study. It was shown that the NO-donor substance DETA/NO, but not inactivated DETA/NO, caused an initial growth inhibition with regrowth noted after 8 h of exposure. An hmp-deficient strain showed a prolonged growth inhibition in response to DETA/NO compared to the wild type. The imidazole antibiotic miconazole, that has been shown to inhibit bacterial flavohemoglobin activity, prolonged the DETA/NO-evoked growth inhibition. When miconazole was combined with polymyxin B nonapeptide (PMBN), in order to increase the bacterial wall permeability, DETA/NO caused a prolonged bacteriostatic response that lasted for up to 24 h.

Conclusion

An NO-donor in combination with miconazole and PMBN showed enhanced antimicrobial effects and proved effective against multidrug-resistant ESBL-producing uropathogenic E. coli.

【 授权许可】

   
2014 Sahlberg Bang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Fang FC: Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2004, 2(10):820-832.
• [2]Smith SD, Wheeler MA, Weiss RM: Nitric oxide synthase: an endogenous source of elevated nitrite in infected urine. Kidney Int 1994, 45(2):586-591.
• [3]Wheeler MA, Smith SD, Garcia-Cardena G, Nathan CF, Weiss RM, Sessa WC: Bacterial infection induces nitric oxide synthase in human neutrophils. J Clin Invest 1997, 99(1):110-116.
• [4]Robinson JL, Brynildsen MP: A kinetic platform to determine the fate of nitric oxide in Escherichia coli. PLoS Comput Biol 2013, 9(5):e1003049.
• [5]Carlsson S, Weitzberg E, Wiklund P, Lundberg JO: Intravesical nitric oxide delivery for prevention of catheter-associated urinary tract infections. Antimicrob Agents Chemother 2005, 49(6):2352-2355.
• [6]Svensson L, Marklund BI, Poljakovic M, Persson K: Uropathogenic Escherichia coli and tolerance to nitric oxide: the role of flavohemoglobin. J Urol 2006, 175(2):749-753.
• [7]Bower JM, Gordon-Raagas HB, Mulvey MA: Conditioning of uropathogenic Escherichia coli for enhanced colonization of host. Infect Immun 2009, 77(5):2104-2112.
• [8]Gardner PR, Gardner AM, Martin LA, Salzman AL: Nitric oxide dioxygenase: an enzymic function for flavohemoglobin. Proc Natl Acad Sci U S A 1998, 95(18):10378-10383.
• [9]Poole RK, Hughes MN: New functions for the ancient globin family: bacterial responses to nitric oxide and nitrosative stress. Mol Microbiol 2000, 36(4):775-783.
• [10]Forrester MT, Foster MW: Protection from nitrosative stress: a central role for microbial flavohemoglobin. Free Radic Biol Med 2012, 52(9):1620-1633.
• [11]Membrillo-Hernandez J, Coopamah MD, Anjum MF, Stevanin TM, Kelly A, Hughes MN, Poole RK: The flavohemoglobin of Escherichia coli confers resistance to a nitrosating agent, a "Nitric oxide Releaser," and paraquat and is essential for transcriptional responses to oxidative stress. J Biol Chem 1999, 274(2):748-754.
• [12]Svensson L, Poljakovic M, Save S, Gilberthorpe N, Schon T, Strid S, Corker H, Poole RK, Persson K: Role of flavohemoglobin in combating nitrosative stress in uropathogenic Escherichia coli–implications for urinary tract infection. Microb Pathog 2010, 49(3):59-66.
• [13]Ilari A, Bonamore A, Farina A, Johnson KA, Boffi A: The X-ray structure of ferric Escherichia coli flavohemoglobin reveals an unexpected geometry of the distal heme pocket. J Biol Chem 2002, 277(26):23725-23732.
• [14]Helmick RA, Fletcher AE, Gardner AM, Gessner CR, Hvitved AN, Gustin MC, Gardner PR: Imidazole antibiotics inhibit the nitric oxide dioxygenase function of microbial flavohemoglobin. Antimicrob Agents Chemother 2005, 49(5):1837-1843.
• [15]Nobre LS, Todorovic S, Tavares AF, Oldfield E, Hildebrandt P, Teixeira M, Saraiva LM: Binding of azole antibiotics to Staphylococcus aureus flavohemoglobin increases intracellular oxidative stress. J Bacteriol 2010, 192(6):1527-1533.
• [16]Pitout JD, Laupland KB: Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8(3):159-166.
• [17]Khanfar HS, Bindayna KM, Senok AC, Botta GA: Extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and community settings. J Infect Dev Ctries 2009, 3(4):295-299.
• [18]Hoban DJ, Lascols C, Nicolle LE, Badal R, Bouchillon S, Hackel M, Hawser S: Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009–2010. Diagn Microbiol Infect Dis 2012, 74(1):62-67.
• [19]Bonnet R: Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004, 48(1):1-14.
• [20]Nathan C: Antibiotics at the crossroads. Nature 2004, 431(7011):899-902.
• [21]Onnberg A, Molling P, Zimmermann J, Soderquist B: Molecular and phenotypic characterization of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum beta-lactamases with focus on CTX-M in a low-endemic area in Sweden. APMIS 2011, 119(4–5):287-295.
• [22]Keefer LK, Nims RW, Davies KM, Wink DA: "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol 1996, 268:281-293.
• [23]Vaara M: Agents that increase the permeability of the outer membrane. Microbiol Rev 1992, 56(3):395-411.
• [24]Pullan ST, Monk CE, Lee L, Poole RK: Microbial responses to nitric oxide and nitrosative stress: growth, "omic," and physiological methods. Methods Enzymol 2008, 437:499-519.
• [25]Hyduke DR, Jarboe LR, Tran LM, Chou KJ, Liao JC: Integrated network analysis identifies nitric oxide response networks and dihydroxyacid dehydratase as a crucial target in Escherichia coli. Proc Natl Acad Sci U S A 2007, 104(20):8484-8489.
• [26]Grandesso S, Sapino B, Mazzucato S, Alessandrini R, Solinas M, Gion M: Study on in-vitro susceptibility of ESBL-positive Escherichia coli isolated from urine specimens. Infez Med 2010, 18(3):162-168.
• [27]Vanden Bossche H, Marichal P, Gorrens J, Coene MC, Willemsens G, Bellens D, Roels I, Moereels H, Janssen PA: Biochemical approaches to selective antifungal activity. Focus on azole antifungals. Mycoses 1989, 32(Suppl 1):35-52.
• [28]McElhaney-Feser GE, Raulli RE, Cihlar RL: Synergy of nitric oxide and azoles against Candida species in vitro. Antimicrob Agents Chemother 1998, 42(9):2342-2346.
• [29]Cornelissen F, Van den Bossche H: Synergism of the antimicrobial agents miconazole, bacitracin and polymyxin B. Chemotherapy 1983, 29(6):419-427.
• [30]Sahalan AZ, Dixon RA: Role of the cell envelope in the antibacterial activities of polymyxin B and polymyxin B nonapeptide against Escherichia coli. Int J Antimicrob Agents 2008, 31(3):224-227.
• [31]Pietschmann S, Hoffmann K, Voget M, Pison U: Synergistic effects of miconazole and polymyxin B on microbial pathogens. Vet Res Commun 2009, 33(6):489-505.
• [32]Thevissen K, Ayscough KR, Aerts AM, Du W, De Brucker K, Meert EM, Ausma J, Borgers M, Cammue BP, Francois IE: Miconazole induces changes in actin cytoskeleton prior to reactive oxygen species induction in yeast. J Biol Chem 2007, 282(30):21592-21597.
• [33]Deupree SM, Schoenfisch MH: Morphological analysis of the antimicrobial action of nitric oxide on gram-negative pathogens using atomic force microscopy. Acta Biomater 2009, 5(5):1405-1415.
• [34]Svensson L, Save S, Persson K: The effect of nitric oxide on adherence of P-fimbriated uropathogenic Escherichia coli to human renal epithelial cells. BJU Int 2010, 105(12):1726-1731.
• [35]Milan PB, Ivan IM: Catheter-associated and nosocomial urinary tract infections: antibiotic resistance and influence on commonly used antimicrobial therapy. Int Urol Nephrol 2009, 41(3):461-464.
• [36]Regev-Shoshani G, Ko M, Miller C, Av-Gay Y: Slow release of nitric oxide from charged catheters and its effect on biofilm formation by Escherichia coli. Antimicrob Agents Chemother 2010, 54(1):273-279.
• [37]Rogers BA, Sidjabat HE, Paterson DL: Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011, 66(1):1-14.
• [38]Karfunkel D, Carmeli Y, Chmelnitsky I, Kotlovsky T, Navon-Venezia S: The emergence and dissemination of CTX-M-producing Escherichia coli sequence type 131 causing community-onset bacteremia in Israel. Eur J Clin Microbiol Infect Dis 2013, 32(4):513-521.
• [39]Yahav D, Farbman L, Leibovici L, Paul M: Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 2012, 18(1):18-29.
• [40]Ghaffari A, Miller CC, McMullin B, Ghahary A: Potential application of gaseous nitric oxide as a topical antimicrobial agent. Nitric Oxide 2006, 14(1):21-29.
• [41]Friedman A, Blecher K, Sanchez D, Tuckman-Vernon C, Gialanella P, Friedman JM, Martinez LR, Nosanchuk JD: Susceptibility of Gram-positive and -negative bacteria to novel nitric oxide-releasing nanoparticle technology. Virulence 2011, 2(3):217-221.
• [42]Richardson AR, Libby SJ, Fang FC: A nitric oxide-inducible lactate dehydrogenase enables Staphylococcus aureus to resist innate immunity. Science 2008, 319(5870):1672-1676.